litlas
Log inCreate account

Aditya Bardia

Active 2006–2025

240
Papers
36,310
Citations
90
h-index
224
i10-index

Citations

Citations per year for Aditya Bardia1964: 1 citations1978: 1 citations2005: 2 citations2006: 5 citations2007: 38 citations2008: 42 citations2009: 32 citations2010: 30 citations2011: 36 citations2012: 23 citations2013: 84 citations2014: 142 citations2015: 237 citations2016: 230 citations2017: 301 citations2018: 291 citations2019: 1,062 citations2020: 1,657 citations2021: 1,879 citations2022: 1,834 citations2023: 1,840 citations2024: 2,970 citations2025: 1,911 citations2026: 55 citations1965–1977: no citations, so these years are not shown1979–2004: no citations, so these years are not shown

Citation sources

Countries

World map of the countries and regions citing this authorUnited States: 3,991 citing papers, 25.6% of this breakdownChina: 2,147 citing papers, 13.8% of this breakdownItaly: 954 citing papers, 6.1% of this breakdownUnited Kingdom: 758 citing papers, 4.8% of this breakdownGermany: 715 citing papers, 4.6% of this breakdownFrance: 632 citing papers, 4% of this breakdownSpain: 573 citing papers, 3.7% of this breakdownCanada: 439 citing papers, 2.8% of this breakdownAustralia: 421 citing papers, 2.7% of this breakdownJapan: 373 citing papers, 2.4% of this breakdownSwitzerland: 354 citing papers, 2.3% of this breakdownSouth Korea: 337 citing papers, 2.2% of this breakdown
0%25.6%Other 25%

Institutions

Fields

  • Medicine61.5%
  • Biochemistry, Genetics and Molecular Biology29.4%
  • Engineering3.1%
  • Immunology and Microbiology2%
  • Computer Science0.8%
  • Materials Science0.6%
  • Other2.6%

Topics

  • Cancer Cells and Metastasis7.3%
  • Advanced Breast Cancer Therapies6.1%
  • HER2/EGFR in Cancer Research5.6%
  • Cancer Genomics and Diagnostics5%
  • Breast Cancer Treatment Studies4.2%
  • Cancer Immunotherapy and Biomarkers2.4%
  • Other69.4%

Coauthors

All papers

Open in search
  1. Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer

    Authors: Aditya Bardia, Sara A. Hurvitz, Sara M. Tolaney, Delphine Loirat, Kevin Punie, Mafalda Oliveira, Adam Brufsky, Sagar Sardesai, Kevin Kalinsky, Amelia Zelnak, Robert Weaver, Tiffany A. Traina, Florence Dalenc, Philippe Aftimos, Filipa Lynce, Sami Diab, Javier Cortés, Joyce O’Shaughnessy, Véronique Dièras, Cristiano Ferrario, Peter Schmid, Lisa A. Carey, Luca Gianni, Martine Piccart, Sibylle Loibl, David M. Goldenberg, Quan Hong, Martin Olivo, Loretta M. Itri, Hope S. Rugo - New England Journal of Medicine 2021 cited by 1,543

  2. Elacestrant (oral selective estrogen receptor degrader) Versus Standard Endocrine Therapy for Estrogen Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Advanced Breast Cancer: Results From the Randomized Phase III EMERALD Trial

    Authors: François‐Clément Bidard, Virginia Kaklamani, Patrick Neven, Guillermo Streich, Alberto J. Montero, Frédéric Forget, Marie‐Ange Mouret‐Reynier, Joohyuk Sohn, Donatienne Taylor, Kathleen Harnden, Hung T. Khong, Judit Kocsis, Florence Dalenc, Patrick M. Dillon, Sunil Babu, Simon Waters, Ines Deleu, José Á. García-Sáenz, Emilio Bria, Marina Elena Cazzaniga, Janice Lu, Philippe Aftimos, Javier Cortés, Shubin Liu, Giulia Tonini, Dirk Laurent, Nassir Habboubi, Maureen G. Conlan, Aditya Bardia - Journal of Clinical Oncology 2022 cited by 695

  3. Circulating Tumor Cell Clusters Are Oligoclonal Precursors of Breast Cancer Metastasis

    Authors: Nicola Aceto, Aditya Bardia, David T. Miyamoto, Maria Donaldson Collier, Ben S. Wittner, Joel A. Spencer, Min Yu, Adam Pely, Amanda Engstrom, Huili Zhu, Brian W. Brannigan, Ravi Kapur, Shannon L. Stott, Toshi Shioda, Sridhar Ramaswamy, David T. Ting, Charles P. Lin, Mehmet Toner, Daniel A. Haber, Shyamala Maheswaran - Cell 2014 cited by 2,505

  4. Overall survival with sacituzumab govitecan in hormone receptor-positive and human epidermal growth factor receptor 2-negative metastatic breast cancer (TROPiCS-02): a randomised, open-label, multicentre, phase 3 trial

    Authors: Hope S. Rugo, Aditya Bardia, Frederik Marmé, Javier Cortés, Peter Schmid, Delphine Loirat, Olivier Trédan, Eva Ciruelos, Florence Dalenc, P. Gómez Pardo, Komal Jhaveri, Rosemary Delaney, T. Valdez, Hao Wang, Monica Motwani, Oh Kyu Yoon, Wendy Verret, Sara M. Tolaney - The Lancet 2023 cited by 427

  5. Antibody–drug conjugates: Smart chemotherapy delivery across tumor histologies

    Authors: Paolo Tarantino, Roberto Carmagnani Pestana, Chiara Corti, Shanu Modi, Aditya Bardia, Sara M. Tolaney, Javier Cortés, Jean‐Charles Soria, Giuseppe Curigliano - CA A Cancer Journal for Clinicians 2021 cited by 376

  6. Sacituzumab Govitecan-hziy in Refractory Metastatic Triple-Negative Breast Cancer

    Authors: Aditya Bardia, Ingrid A. Mayer, Linda T. Vahdat, Sara M. Tolaney, Steven J. Isakoff, Jennifer R. Diamond, Joyce O’Shaughnessy, Rebecca Moroose, Alessandro D. Santin, Vandana G. Abramson, Nikita Shah, Hope S. Rugo, David M. Goldenberg, Ala M. Sweidan, Robert Iannone, Sarah A. Washkowitz, Robert M. Sharkey, William A. Wegener, Kevin Kalinsky - New England Journal of Medicine 2019 cited by 850

  7. Pathologic Complete Response after Neoadjuvant Chemotherapy and Impact on Breast Cancer Recurrence and Survival: A Comprehensive Meta-analysis

    Authors: Laura M. Spring, Geoffrey Fell, Andrea Arfè, Chandni Sharma, Rachel A. Greenup, Kerry L. Reynolds, Barbara L. Smith, Brian M. Alexander, Beverly Moy, Steven J. Isakoff, Giovanni Parmigiani, Lorenzo Trippa, Aditya Bardia - Clinical Cancer Research 2020 cited by 909

  8. Sacituzumab govitecan, a Trop-2-directed antibody-drug conjugate, for patients with epithelial cancer: final safety and efficacy results from the phase I/II IMMU-132-01 basket trial

    Authors: Aditya Bardia, Wells A. Messersmith, Ebenezer A. Kio, Jordan Berlin, Linda T. Vahdat, Gregory A. Masters, R Moroose, Alessandro D. Santin, Kevin Kalinsky, Vincent J. Picozzi, Joyce O’Shaughnessy, Jhanelle E. Gray, Takefumi Komiya, Joshua M. Lang, Jenny C. Chang, Alexander Starodub, David M. Goldenberg, Robert M. Sharkey, Pius Maliakal, Q. Hong, William A. Wegener, Trishna Goswami, Allyson J. Ocean - Annals of Oncology 2021 cited by 375

  9. Intercellular nanotubes mediate mitochondrial trafficking between cancer and immune cells

    Authors: Tanmoy Saha, Chinmayee Dash, Ruparoshni Jayabalan, Sachin Khiste, Arpita Kulkarni, Kiran Kurmi, Jayanta Mondal, Pradip K. Majumder, Aditya Bardia, Hae Lin Jang, Shiladitya Sengupta - Nature Nanotechnology 2021 cited by 397

  10. Circulating Breast Tumor Cells Exhibit Dynamic Changes in Epithelial and Mesenchymal Composition

    Authors: Min Yu, Aditya Bardia, Ben S. Wittner, Shannon L. Stott, Malgorzata E. Smas, David T. Ting, Steven J. Isakoff, Jordan C. Ciciliano, Marissa Wells, Ajay M. Shah, Kyle Concannon, Maria Donaldson Collier, Lecia V. Sequist, Elena F. Brachtel, Dennis C. Sgroi, José Baselga, Sridhar Ramaswamy, Mehmet Toner, Daniel A. Haber, Shyamala Maheswaran - Science 2013 cited by 2,496

  11. Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): a randomised phase 3 trial

    Authors: Debu Tripathy, Seock‐Ah Im, Marco Colleoni, Fábio Franke, Aditya Bardia, Nadia Harbeck, Sara A. Hurvitz, Louis W.C. Chow, Joohyuk Sohn, Keun Seok Lee, Saúl Campos-Gómez, Rafael Villanueva-Vázquez, Kyung Hae Jung, Govind Babu, Paul Wheatley‐Price, Michelino De Laurentiis, Young‐Hyuck Im, Sherko Küemmel, Nagi S. El-Saghir, Mei-Ching Liu, Gary P. Carlson, Gareth Hughes, Iván Díaz-Padilla, Caroline Germa, Samit Hirawat, Yen‐Shen Lu - The Lancet Oncology 2018 cited by 1,011

  12. Sacituzumab Govitecan in Hormone Receptor–Positive/Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer

    Authors: Hope S. Rugo, Aditya Bardia, Frederik Marmé, Javier Cortés, Peter Schmid, Delphine Loirat, Olivier Trédan, Eva Ciruelos, Florence Dalenc, P. Gómez Pardo, Komal Jhaveri, Rosemary Delaney, Olivia Fu, Lanjia Lin, Wendy Verret, Sara M. Tolaney - Journal of Clinical Oncology 2022 cited by 298

  13. Trastuzumab Deruxtecan after Endocrine Therapy in Metastatic Breast Cancer

    Authors: Aditya Bardia, Xichun Hu, Rebecca Dent, Kan Yonemori, Carlos H. Barrios, Joyce O’Shaughnessy, Hans Wildiers, Jean‐Yves Pierga, Qingyuan Zhang, Cristina Saura, Laura Biganzoli, Joohyuk Sohn, Seock‐Ah Im, Christelle Lévy, William Jacot, Natasha Begbie, Jun Ke, Gargi Patel, Giuseppe Curigliano - New England Journal of Medicine 2024 cited by 393

  14. Overall Survival with Ribociclib plus Endocrine Therapy in Breast Cancer

    Authors: Seock‐Ah Im, Yen‐Shen Lu, Aditya Bardia, Nadia Harbeck, Marco Colleoni, Fábio Franke, Louis W.C. Chow, Joohyuk Sohn, Keun-Seok Lee, Saúl Campos-Gómez, Rafael Villanueva-Vázquez, Kyung-Hae Jung, Arunava Chakravartty, Gareth Hughes, Ioannis Gounaris, Karen Rodriguez-Lorenc, Tetiana Taran, Sara A. Hurvitz, Debu Tripathy - New England Journal of Medicine 2019 cited by 1,021

  15. ESR1 mutation as an emerging clinical biomarker in metastatic hormone receptor-positive breast cancer

    Authors: Jamie O. Brett, Laura M. Spring, Aditya Bardia, Seth A. Wander - Breast Cancer Research 2021 cited by 412

  16. Ribociclib plus Endocrine Therapy in Early Breast Cancer

    Authors: Dennis J. Slamon, Oleg Lipatov, Zbigniew Nowecki, Nicholas P. McAndrew, Bożena Kukiełka-Budny, Daniil Stroyakovskiy, Denise A. Yardley, Chiun‐Sheng Huang, Peter A. Fasching, John Crown, Aditya Bardia, Stephen Chia, Seock‐Ah Im, Manuel Ruíz-Borrego, Sherene Loi, Binghe Xu, Sara A. Hurvitz, Carlos H. Barrios, Michael Untch, Rebecca Moroose, F. Visco, Karen Afenjar, Rodrigo Fresco, Irene Severin, Yan Ji, Farhat Ghaznawi, Zheng Li, Juan Pablo Zarate, Arunava Chakravartty, Tetiana Taran, Gabriel N. Hortobágyi - New England Journal of Medicine 2024 cited by 357

  17. Parallel Genomic Alterations of Antigen and Payload Targets Mediate Polyclonal Acquired Clinical Resistance to Sacituzumab Govitecan in Triple-Negative Breast Cancer

    Authors: James T. Coates, Sheng Sun, Ignaty Leshchiner, Nayana Thimmiah, Elizabeth E. Martin, Daniel E. McLoughlin, Brian P. Danysh, Kara Slowik, Raquel A. Jacobs, Kahn Rhrissorrakrai, Filippo Utro, Chaya Levovitz, Elyssa N. Denault, Charlotte S. Walmsley, Avinash Kambadakone, James R. Stone, Steven J. Isakoff, Laxmi Parida, Dejan Juric, Gad Getz, Aditya Bardia, Leif W. Ellisen - Cancer Discovery 2021 cited by 223

  18. Biomarker analyses in the phase III ASCENT study of sacituzumab govitecan versus chemotherapy in patients with metastatic triple-negative breast cancer

    Authors: Aditya Bardia, Sara M. Tolaney, Kevin Punie, Delphine Loirat, Mafalda Oliveira, Kevin Kalinsky, Amelia Zelnak, Philippe Aftimos, Florence Dalenc, Sagar Sardesai, Erika Hamilton, Priyanka Sharma, Sabela Recalde, Eva Ciruelos Gil, T Traina, Joyce O’Shaughnessy, Javier Cortés, Mu‐Hung Tsai, Linda T. Vahdat, Véronique Dièras, Lisa A. Carey, Hope S. Rugo, David M. Goldenberg, Q. Hong, Martin Olivo, Loretta M. Itri, Sara A. Hurvitz - Annals of Oncology 2021 cited by 299

  19. Impact of HER2 Heterogeneity on Treatment Response of Early-Stage HER2-Positive Breast Cancer: Phase II Neoadjuvant Clinical Trial of T-DM1 Combined with Pertuzumab

    Authors: Otto Metzger, Giuseppe Viale, Shayna Stein, Lorenzo Trippa, Denise A. Yardley, Ingrid A. Mayer, Vandana G. Abramson, Carlos L. Arteaga, Laura M. Spring, Adrienne G. Waks, Eileen Wrabel, Michelle K. DeMeo, Aditya Bardia, Patrizia Dell’Orto, Leila Russo, Tari A. King, Kornélia Polyák, Franziska Michor, Eric P. Winer, Ian E. Krop - Cancer Discovery 2021 cited by 240

  20. LBA21 KEYNOTE-756: Phase III study of neoadjuvant pembrolizumab (pembro) or placebo (pbo) + chemotherapy (chemo), followed by adjuvant pembro or pbo + endocrine therapy (ET) for early-stage high-risk ER+/HER2– breast cancer

    Authors: Fátima Cardoso, Heather L. McArthur, Peter Schmid, Javier Cortés, Nadia Harbeck, Melinda L. Telli, David W. Cescon, Joyce O’Shaughnessy, Peter A. Fasching, Zhi-Min Shao, Delphine Loirat, Y.H. Park, María Ángeles Fernández, Z. Liu, Hiroyuki Yasojima, Yu Ding, L. Jia, Vassiliki Karantza, Konstantinos Tryfonidis, Aditya Bardia - Annals of Oncology 2023 cited by 134

  21. Cyclin-dependent kinase 4 and 6 inhibitors for hormone receptor-positive breast cancer: past, present, and future

    Authors: Laura M. Spring, Seth A. Wander, Fabrice André, Beverly Moy, Nicholas C. Turner, Aditya Bardia - The Lancet 2020 cited by 466

  22. Updated Overall Survival of Ribociclib plus Endocrine Therapy versus Endocrine Therapy Alone in Pre- and Perimenopausal Patients with HR+/HER2− Advanced Breast Cancer in MONALEESA-7: A Phase III Randomized Clinical Trial

    Authors: Yen-Shen Lu, Seock-Ah Im, Marco Colleoni, Fabio Franke, Aditya Bardia, Fatima Cardoso, Nadia Harbeck, Sara Hurvitz, Louis Chow, Joohyuk Sohn, Keun Seok Lee, Saul Campos-Gomez, Rafael Villanueva Vazquez, Kyung Hae Jung, K. Govind Babu, Paul Wheatley-Price, Michelino De Laurentiis, Young-Hyuck Im, Sherko Kuemmel, Nagi El-Saghir, Ruth O'Regan, Claudia Gasch, Nadia Solovieff, Craig Wang, Yongyu Wang, Arunava Chakravartty, Yan Ji, Debu Tripathy - Clinical Cancer Research 2021 cited by 263

  23. Deregulation of ribosomal protein expression and translation promotes breast cancer metastasis

    Authors: Richard Y. Ebright, Sooncheol Lee, Ben S. Wittner, Kira Niederhoffer, Benjamin Nicholson, Aditya Bardia, Samuel S. Truesdell, Devon F. Wiley, Benjamin Wesley, Selena S. Li, Andy Mai, Nicola Aceto, Nicole Vincent-Jordan, Annamária Szabolcs, Brian Chirn, Johannes Kreuzer, Valentine Comaills, Mark Kalinich, Wilhelm Haas, David T. Ting, Mehmet Toner, Shobha Vasudevan, Daniel A. Haber, Shyamala Maheswaran, Douglas S. Micalizzi - Science 2020 cited by 377

  24. Mechanisms of Resistance to Antibody–Drug Conjugates

    Authors: Rachel O. Abelman, Bogang Wu, Laura M. Spring, Leif W. Ellisen, Aditya Bardia - Cancers 2023 cited by 137